---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-076085"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:07:17.485561+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adial reports FDA agreement on Phase 3 design for AD04; Q2 net loss $2.0M, cash $5.9M

## Summary
- Completed End of Phase 2 meeting with FDA; agreement on key Phase 3 protocol elements for AD04 in Alcohol Use Disorder.
- Cash and equivalents $5.9M as of June 30, 2025 (up from $2.4M at March 31); cash runway into Q2 2026.
- Public offering closed June 17, 2025 raised net proceeds ~$3.0M from 11.1M shares and warrants at $0.3251.
- Entered manufacturing agreements with Thermo Fisher Scientific and Cambrex for AD04 drug product and substance.
- Regained Nasdaq compliance on July 14, 2025 for minimum stockholders' equity of $2.5M.

## SEC filing metadata
- accession: 0001213900-25-076085
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/0001213900-25-076085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/ea0252930-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-076085
- JSON: https://secwatch.observer/filing/0001213900-25-076085.json
- Plain text: https://secwatch.observer/filing/0001213900-25-076085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.